Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2018

View Archived Issues

Deleterious mutations in SQSTM1 cause early onset neurodegeneration

Cannabis-schizophrenia association goes both ways, but unequally

How cirrhosis drug fights Alzheimer's disease

HDAC inhibition can help in DNA repair syndrome

Methylation of MORC1 predicts depression risk in humans

RegenxBio announces development of new candidate RGX-181 for CLN2 form of Batten disease

Phase I trial of Adverum's ADVM-022 gene therapy for wAMD to begin in Q4

Initial single-dose data presented from phase I study of NasoShield

Darzalex receives approval in Europe as treatment of newly diagnosed multiple myeloma

FKBP5 strikes again: Gene variant affects risk of developing chronic pain after trauma

MAP17 levels predict sensitivity of lung adenocarcinoma to chemotherapy

Development of a universally effective influenza virus

Capella BioSience describes antibodies targeting LIGHT

Invictus Oncology patents CSF1R inhibitors

Nuclear receptor RORgammaT agonists synthesized at Fudan University

Praxis Precision Medicines discovers sodium channel protein type 8 subunit alpha blockers

Cavion divulges new calcium channel inhibitors

FDA issues complete response letter for dasotraline NDA for ADHD

European Commission approves Cablivi for acquired thrombotic thrombocytopenic purpura

Incyte studies INCAGN-02385 in phase I for advanced malignancies

New phase II trial investigates MT-3724 with GEMOX in NHL

AstraZeneca conducts first-in-human study of AZD-8154 in healthy subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...